• Valion Bio confirmed a U.S. House Armed Services Committee initiative in the FY27 NDAA process to prioritize radiation and nuclear medical countermeasures.
• The directive calls for a resources and fielding plan for countermeasures with both pre-exposure radioprotectant and post-exposure radiomitigant use.
• The update follows April and May 2026 briefings with senior Department of War officials and BARDA on Entolimod for acute radiation syndrome.
• Entolimod showed survival benefits as both a radioprotectant and radiomitigant in non-human primate studies under the FDA’s Animal Rule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.